Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06703190 · ClinicalTrials.gov registry record
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 1
- Enrollment target
NCT06703190: Clinical Trial study, sponsored by Pfizer.
NCT06703190 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06703190 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing for SARS-CoV-2, across different age groups, during periods of various variant circulation, and by months since receipt of vaccine dose.
Primary Outcome
Exposed Cases will be defined as patients testing positive for SARS-CoV-2 infection by RAT at a CVS MinuteClinic and reporting at least one COVID-19 symptom and were vaccinated with the 2024-2025 formulation of the Pfizer/BioNTech vaccine ≥14 days prior to testing.
Interventions
- BIOLOGICAL Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated
- BIOLOGICAL Not vaccinated with 2024-2025 formulated COVID-19 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2025-06-06 |
Why NCT06703190 stopped before completion
NCT06703190 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated is the first listed.
NCT06703190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06703190 about?
NCT06703190 is a clinical study titled "Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine". This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing for SARS-CoV-2, across different age groups, during periods of various ...
What is the current status of trial NCT06703190?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2024-11-25. Estimated completion is 2025-06-06.
What interventions are being tested in trial NCT06703190?
The interventions under investigation include: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated (BIOLOGICAL), Not vaccinated with 2024-2025 formulated COVID-19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06703190?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI